# Temple University Gastroparesis Clinical Center

> **NIH NIH U01** · TEMPLE UNIV OF THE COMMONWEALTH · 2022 · $1

## Abstract

PROJECT SUMMARY
Patients with gastroparesis often suffer with chronic symptoms that are not adequately treated due to both a
lack of understanding of the underlying pathophysiology of gastroparesis and lack of effective treatments.
Participation of Temple University as a clinical center in the NIDDK Gastroparesis Clinical Research
Consortium (GpCRC) and Temple's proposed studies will help achieve the broad, long term objectives of
improving the understanding and treatment of patients with gastroparesis. The PI and Temple University are
well qualified to continue to be one of the clinical centers in the GpCRC. Temple University has extensive
clinical expertise in gastroparesis and has been active in study development, enrolling patients into studies,
manuscript publication, and obtaining funding for ancillary studies. The aims for Temple's renewal for the
GpCRC are threefold. First, to continue enrollment and follow-up of patients in current GpCRC studies: GpR3,
BESST, PBG, PSAG. We will maintain the Gastroparesis Registry 3 (GpR3) to enroll 400 patients with follow-
up on patients for 1 to 4 years. GpR3 was recently enhanced to study the effects of SARS-CoV-2 in patients
with gastroparesis. We continue to enroll in the clinical trial Buspirone for Early Satiety and Symptoms of
Gastroparesis (BESST). Our Pathological Basis of Gastroparesis (PBG) is studying immune cell profiles in
gastroparesis. We will start our study on pyloric pathophysiology: Pyloric Sphincter Abnormalities in Patients
with Gastroparesis Symptoms (PSAGS). Second, to better understand the clinical manifestations and
pathophysiology of patients with symptoms of gastroparesis, we will start a new registry, Gastroparesis
Registry 4 for enrollment of 400 new patients. This application includes suggestions for five areas of study: 1)
evaluating for autoimmune gastroparesis; 2) understanding meal eating characteristics and ARFID-like
symptoms in patients with gastroparesis; 3) assess for hypocortisolism which can occur in gastroparesis
patients and add to the symptom severity; 4) assessing for vagal and peripheral neuropathy as
pathophysiologic comorbidities in gastroparesis; and 5) further enhancement of gastric emptying scintigraphy
(GES) assessing antral synchronicity and antropyloroduodenal coordination. Third, to conduct a new
multicenter study investigating the pathophysiology, diagnosis, and treatment of gastroparesis. Our application
proposes a new study, Relating Gastric Pathophysiology using GES with DACS to Treatment Outcome, aimed
at understanding the pathophysiologic basis of gastroparesis and its relationship to symptoms. The goal is to
better target specific treatment based on pathophysiology and symptoms. Temple's participation and proposed
studies will help achieve the goal of the NIDDK GpCRC to advance our understanding and treatment of
gastroparesis.

## Key facts

- **NIH application ID:** 10319870
- **Project number:** 2U01DK073975-16
- **Recipient organization:** TEMPLE UNIV OF THE COMMONWEALTH
- **Principal Investigator:** HENRY PAUL PARKMAN
- **Activity code:** U01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $1
- **Award type:** 2
- **Project period:** 2006-04-15 → 2027-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10319870

## Citation

> US National Institutes of Health, RePORTER application 10319870, Temple University Gastroparesis Clinical Center (2U01DK073975-16). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10319870. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*